Opdivo (nivolumab) pricing across global markets. 0 countries tracked, with reimbursement status, annual cost in USD, and currency conversion. Sourced from public reimbursement lists and manufacturer disclosures.
Country-by-country comparison
No pricing data tracked for this drug yet. The drug_pricing table covers ~40% of marketed drugs in major countries — we're actively expanding coverage.
Important caveats
List vs net: what's shown is the manufacturer's list price (WAC in the US, public list price elsewhere). Actual payer + patient costs are after rebates, copay assistance, and insurance contributions, which can be 30–60% lower.
Indication-dependent: some drugs have different prices for different indications or strengths. Where multiple are tracked, the most-common adult dose is shown.
USD conversion: annual_cost_usd is converted at our most recent FX rate. Local currency is the authoritative figure.
Coverage: reimbursement_status reflects whether a public payer reimburses the drug, not whether any commercial plan does.
Subscribe to pricing updates
Get every Opdivo regulatory + pricing change in your RSS reader: